Historical Valuation
Lyra Therapeutics Inc (LYRA) is now in the Fair zone, suggesting that its current forward PS ratio of 5.34 is considered Fairly compared with the five-year average of -2.08. The fair price of Lyra Therapeutics Inc (LYRA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.77
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lyra Therapeutics Inc (LYRA) has a current Price-to-Book (P/B) ratio of -1.20. Compared to its 3-year average P/B ratio of 1.69 , the current P/B ratio is approximately -170.91% higher. Relative to its 5-year average P/B ratio of 1.77, the current P/B ratio is about -167.84% higher. Lyra Therapeutics Inc (LYRA) has a Forward Free Cash Flow (FCF) yield of approximately -608.12%. Compared to its 3-year average FCF yield of -304.24%, the current FCF yield is approximately 99.88% lower. Relative to its 5-year average FCF yield of -192.19% , the current FCF yield is about 216.41% lower.
P/B
Median3y
1.69
Median5y
1.77
FCF Yield
Median3y
-304.24
Median5y
-192.19
Competitors Valuation Multiple
AI Analysis for LYRA
The average P/S ratio for LYRA competitors is 5.42, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA.O) exhibits a P/S ratio of 5.34, which is -1.53% above the industry average. Given its robust revenue growth of -87.18%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LYRA
1Y
3Y
5Y
Market capitalization of LYRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LYRA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LYRA currently overvalued or undervalued?
Lyra Therapeutics Inc (LYRA) is now in the Fair zone, suggesting that its current forward PS ratio of 5.34 is considered Fairly compared with the five-year average of -2.08. The fair price of Lyra Therapeutics Inc (LYRA) is between to according to relative valuation methord.
What is Lyra Therapeutics Inc (LYRA) fair value?
LYRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lyra Therapeutics Inc (LYRA) is between to according to relative valuation methord.
How does LYRA's valuation metrics compare to the industry average?
The average P/S ratio for LYRA's competitors is 5.42, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA) exhibits a P/S ratio of 5.34, which is -1.53% above the industry average. Given its robust revenue growth of -87.18%, this premium appears unsustainable.
What is the current P/B ratio for Lyra Therapeutics Inc (LYRA) as of Jan 11 2026?
As of Jan 11 2026, Lyra Therapeutics Inc (LYRA) has a P/B ratio of -1.20. This indicates that the market values LYRA at -1.20 times its book value.
What is the current FCF Yield for Lyra Therapeutics Inc (LYRA) as of Jan 11 2026?
As of Jan 11 2026, Lyra Therapeutics Inc (LYRA) has a FCF Yield of -608.12%. This means that for every dollar of Lyra Therapeutics Inc’s market capitalization, the company generates -608.12 cents in free cash flow.
What is the current Forward P/E ratio for Lyra Therapeutics Inc (LYRA) as of Jan 11 2026?
As of Jan 11 2026, Lyra Therapeutics Inc (LYRA) has a Forward P/E ratio of -0.38. This means the market is willing to pay $-0.38 for every dollar of Lyra Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lyra Therapeutics Inc (LYRA) as of Jan 11 2026?
As of Jan 11 2026, Lyra Therapeutics Inc (LYRA) has a Forward P/S ratio of 5.34. This means the market is valuing LYRA at $5.34 for every dollar of expected revenue over the next 12 months.